Literature DB >> 6787963

Epithelial carcinoma of the ovary: current strategies.

M E Katz, P E Schwartz, D S Kapp, S Luikart.   

Abstract

Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV). Recent advances in chemotherapy and radiation therapy offer the possibility of long-term disease-free survival and the potential for cure. The selection of treatment for disease confined to the pelvis (stage I or II) remains controversial. After total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy, high risk patients probably should receive abdominopelvic irradiation or chemotherapy; the relative roles of these two modalities are currently under study. Stage III consists of cases of minimal residual disease at surgery, minimal residual disease after debulking surgery, and residual large bulky tumor masses. Patients with minimal residual disease are best treated with either abdominopelvic radiation or chemotherapy; patients with stage IV or bulky stage III disease, with chemotherapy. Despite the multiplicity of active single agents, only one study to date has shown a statistically significant improvement in survival for patients with advanced disease utilizing combination chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6787963     DOI: 10.7326/0003-4819-95-1-98

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Synthesis and antitumor activity of a series of (aminoethylpyrrolidine) platinum complexes.

Authors:  A R Khokhar; D B Brown; J J McCormack; M P Hacker
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 3.  Chemotherapy in advanced ovarian cancer.

Authors:  C J Rodenburg; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 4.  Pharmaceutical management of ovarian cancer : current status.

Authors:  Maurie Markman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.

Authors:  C Redman; F Lawton; N Stuart; M O'Brien; J Buxton; J Mould; A Chetiyawardana; M Crawford; M Patterson; V Sykes
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.

Authors:  J Carmo-Pereira; F O Costa; E Henriques
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.

Authors:  H E Lambert; R J Berry
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

Review 8.  Intraperitoneal therapy in the management of ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

Review 9.  Early detection of ovarian cancer: background, rationale, and structure of the Yale Early Detection Program.

Authors:  P E Schwartz; J T Chambers; K J Taylor; J Pellerito; L Hammers; L A Cole; T L Yang-Feng; P Smith; S T Mayne; R Makuch
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec

10.  Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma.

Authors:  S Kehoe; C Redman; R Varma; J Buxton; D Luesley; G Blackledge; A Stanley
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.